Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 172Esophageal Neoplasms 161Esophageal Squamous Cell Carcinoma 116Cholangiocarcinoma 77Pancreatic Neoplasms 73Biliary Tract Neoplasms 72Adenocarcinoma Of Esophagus 52Gallbladder Neoplasms 39Colorectal Neoplasms 36Neoplasm Metastasis 30Carcinoma, Non-Small-Cell Lung 28Carcinoma, Hepatocellular 28Neoplasms 27Bile Duct Neoplasms 24Ovarian Neoplasms 19Liver Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 15Colonic Neoplasms 13Peritoneal Neoplasms 12Gastrointestinal Neoplasms 12Anus Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Adenocarcinoma 11Rectal Neoplasms 9Melanoma 9Lung Neoplasms 9Carcinoma, Squamous Cell 9Breast Neoplasms 9Sarcoma 8Hepatoblastoma 8

Interventions

Trastuzumab 5Oxaliplatin 4Capecitabine 3trastuzumab deruxtecan 2tislelizumab 2disitamab vedotin 2Tegafur 2Fluorouracil 2Cisplatin 2tucatinib 1pembrolizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Cisplatin × Gastrointestinal × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡